HUMANIGEN BUY | USD30 With more setbacks among competitors, the path is cleared up for lenzilumab
HUMANIGEN BUY | USD30With more setbacks among competitors, the path is cleared up for lenzilumab
While not meeting primary endpoint, otilimab showed clinical activity
Otilimab’s results bode well for lenzilumab
MK-7110 had a setback with regulators, pushing the EUA down the road
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.